Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction

对患有获得性 CFTR 功能障碍的 COPD 雪貂进行新型 CFTR 增效剂的评估

阅读:11
作者:Niroop Kaza, Vivian Y Lin, Denise Stanford, Shah S Hussain, Emily Falk Libby, Harrison Kim, Monica Borgonovi, Katja Conrath, Venkateshwar Mutyam, Stephen A Byzek, Li Ping Tang, John E Trombley, Lawrence Rasmussen, Trenton Schoeb, Hui Min Leung, Guillermo J Tearney, S Vamsee Raju, Steven M Rowe

Conclusions

The pharmacologic reversal of acquired CFTR dysfunction is beneficial against pathological features of chronic bronchitis in a COPD ferret model.

Methods

Ferrets were exposed for 6 months to cigarette smoke to induce COPD and chronic bronchitis and then treated with enteral GLPG2196 once daily for 1 month. Electrophysiological measurements of ion transport and CFTR function, assessment of mucociliary function by one-micron optical coherence tomography imaging and particle-tracking microrheology, microcomputed tomography imaging, histopathological analysis and quantification of CFTR protein and mRNA expression were used to evaluate mechanistic and pathophysiological changes. Measurements and main

Results

Following cigarette smoke exposure, ferrets exhibited CFTR dysfunction, increased mucus viscosity, delayed mucociliary clearance, airway wall thickening and airway epithelial hypertrophy. In COPD ferrets, GLPG2196 treatment reversed CFTR dysfunction, increased mucus transport by decreasing mucus viscosity, and reduced bronchial wall thickening and airway epithelial hypertrophy. Conclusions: The pharmacologic reversal of acquired CFTR dysfunction is beneficial against pathological features of chronic bronchitis in a COPD ferret model.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。